Omega Diagnostics Share Discussion Threads

[gadg3t] 28/9/2007 08:24

Omega Diagnostics Group PLC
26 September 2007

Omega Diagnostics Group PLC ('the Company')

Notifiable Interest



A form TR-1 containing the following information has been received by the
Company.

TR-1 notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached:

Omega Diagnostics Group PLC

2. Reason for the notification

Acquisition of Voting Rights

3. Full name of person(s) subject to the notification obligation:

New Star Asset Management Limited

4. Full name of shareholder(s) (if different from 3):

N/A

5. Date of the transaction (and date on which the threshold is crossed or
reached if different):

29th August 2007

6. Date on which issuer notified:

25th September 2007

7. Threshold(s) that is/are crossed or reached:

5%

8. Notified details:

A: Voting rights attached to shares
Class/type of Situation previous to Resulting situation after the triggering transaction
shares Triggering
transaction Notification required under DTR transitional provision 7
if possible using
ISIN CODE
Number of Number of Number of Number of voting rights % of voting rights
Shares Voting shares
Rights Direct Direct Indirect Direct Indirect


ORD SHARES 166,666 1.12% 833,332 5.60%

B: Financial Instruments
Resulting situation after the triggering transaction


Type of financial Expiration date Exercise/ Number of voting % of voting rights
instrument Conversion Period/ rights that may be
Date acquired if the
instrument is
exercised/ converted




Total (A+B)
Number of voting rights % of voting rights


833,332 5.60%



9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

N/A

10. Name of the Proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

N/A

14. Contact name:

N/A

15. Contact telephone number:

N/A

[smiler 0] 26/9/2007 20:06

Not Sure about topping up to bring down my avg ? any guess as to what price say in 6 to 12 months could be ?

[frederico3] 26/9/2007 16:23

Should see a nice rise in these with a little buying. At least the mms are bidding for stock, which they haven't been doing for days.

As tinker said these are now 20% lower to buy than the price the directors got. Cheap at present.

[frederico3] 26/9/2007 15:59

I can also buy and sell now on selftrade,it has taken time..Maybe we will start to see some interest here. RNS today re a significant holdng.

And a few buys today.

[rheiner] 26/9/2007 11:16

Tinker Tailor : You can now buy ODX on Selftrade. Just picked up 8000 at 24p but it takes a long time to show up on 'Trades'

[rheiner] 26/9/2007 10:07

Frederico3 :- I agree completely with your post. These are now cheaper than the Directors' buys a few weeks ago. They are at the equivalent of the previous low prior to consolidation. Shares in issue now only about 14m. so any news or interest and these will move positively.

[frederico3] 26/9/2007 08:34

These look very cheap now. Shares in issue are wrong on the ADVFn fundamentals. Only about 4 million in free float, a little buying and these will move quickly.

[tinker tailor] 03/9/2007 12:56

I only have a Selftrade account and it won't let me.

[snake_pleskin] 03/9/2007 12:29

CaN BUY WITH td waterhouse, cant buy yet with selftrade

[smiler 0] 03/9/2007 12:15

Can buy on line now with barclays !

[snake_pleskin] 03/9/2007 11:53

Hence no price movement. The shares appear to be un-tradeable at present.

[tinker tailor] 03/9/2007 11:51

Can anyone buy online at present.Still no joy here.

[tinker tailor] 03/9/2007 08:27

Still cannot purchase online.

[smiler 0] 03/9/2007 08:22

Omega Diagnostics Group PLC
03 September 2007



Omega Diagnostics Group plc

Completion of Acquisition

Omega Diagnostics Group plc ('Omega'), the AIM listed medical diagnostic
company, announces that it has completed the acquisition of the entire issued
share capital of Genesis Diagnostics Limited and Cambridge Nutritional Sciences
Limited (together 'Genesis-CNS').

Genesis-CNS is a growing, profitable, cash-generative business serving the
clinical and consumer diagnostics markets. Genesis-CNS supplies test kits to
hospital laboratories in the UK and overseas, via a network of distributors, in
27 countries. In addition Genesis-CNS offers food intolerance test services to
healthcare practitioners and has developed a home test kit for food intolerance
which has received the CE mark and can be sold to consumers directly. The
company has also developed two complementary technologies, the macro- and the
microarray which it currently utilises in its own products and services.

At the EGM on 30 August 2007 shareholders approved the completion of the
Acquisition, the Placing, the Share Consolidation and the Capital Reorganisation
and this morning the Second Admission Shares were admitted to trading on AIM.
Further to the announcement on 30 August 2007 the Company's issued share capital
now consists of 14,875,693 New Ordinary Shares of 4 pence each.

Initial Consideration and Funding

Initial consideration payable for the Acquisition was £5.7m and was payable as
follows:

(a) £3.2 million payable in cash at Completion (approximately £2.9 million net
of the cash on Genesis - CNS' balance sheet at Completion);

(b) the issue of 4,461,220 Consideration Shares at the Placing Price and an
amount in cash of £61,634 payable one year after Completion; and

(c) the issue of a loan note in respect of £1.1 million on Completion.

In order to fund the Acquisition the Company raised £2.2 million by means of a
placing of 7,333,333 New Ordinary Shares at 30p (0.75p before reorganisation and
consolidation) by Landsbanki Securities (UK) Limited. A further £1.2 million of
funding for the Acquisition has been provided by a loan from Bank of Scotland.

[aiminvestor] 02/9/2007 21:59

Now that the purchases of Genesis-CNS have gone through I am quite sure these will rally based on the results of the company as a whole.The fundamentals look exceptionally good and these are presently off the mainstream radar.

As can be seen Genesis-CNS are trading profitably and the integration will lead to additional cost cuts which will have a positive impact on the companies trading in future years.

[tinker tailor] 02/9/2007 19:59

Here is a very interesting sector article

[tinker tailor] 02/9/2007 13:34

gadg that is the beauty of getting in before the hoards descend.The potential now of Omega is just being realised and Investors are now taking a much greater interest having seen the figures reported from the recent aquisitions.They now have "some meat on the bone" where are before there was speculation.

[gadg3t] 01/9/2007 12:58

Still needs to get noticed this share, But has huge potential and agree we could start to see some increase in the share price in the near future !

[tinker tailor] 01/9/2007 12:08

Well looking over the results for the two new companies I have determined this is now very undervalued and with the cost savings which can be implemented with the integration of all three do expect to see a very strong day on Monday when trading is opened up.

[tinker tailor] 31/8/2007 23:14

INFORMATION ON OMEGA

Omega is an established business in the medical diagnostics industry which
produces and sells a wide range of immunoassay and infectious disease IVD test
kits and other products through a distribution network in more than 100
countries worldwide. Omega operates in a niche market, supplying tests for
specific infectious diseases and other clinical conditions. The infectious
diseases addressed by Omega's products include Syphilis, Tuberculosis, Dengue
Fever, Chagas Disease and Malaria. All products are designed for use in clinical
laboratories and Rapid Tests are designed for use at the point of care. Omega
currently exports over 95 per cent. of its products.


INFORMATION ON GENESIS-CNS

Genesis and CNS are established businesses in the medical diagnostics industry
which develop, produce and sell a range of IVD tests kits specialising in the
areas of autoimmune disease, infectious disease and food intolerance. The
acquisition of Genesis-CNS is in line with Omega's strategy of focusing on
selected acquisitions of niche players in the IVD market. Genesis-CNS has the
following characteristics which make it an attractive acquisition for the
Company:

- Growing, profitable, cash-generative

- Operating in growth markets

- Ability to increase the routes to market

- Complementary product ranges

- Well established high quality management team

[snake_pleskin] 31/8/2007 23:12

By the way just 4.5 million shares in free float, these could screech past £1 on monday...I bet the MMs hold less than 100k. Earlybirds will catch the big increases.

[snake_pleskin] 31/8/2007 23:09

Im not saying that, im saying they got a bargain..We have to pay 37p..or 1p in old value. Anyway a little company info below.

Introduction
Omega Diagnostics Group PLC was established in September 2006 when Omega Diagnostics Limited completed a "reverse acquisition" of an AIM Listed Cash Shell Company called Quintessentially English PLC.

Omega Diagnostics Limited (Omega) is an established business in the medical diagnostics market. Omega sells a wide range of products primarily in the immunoassay and infectious disease in-vitro diagnostics (IVD) market through a strong distribution network in over 100 countries. Omega has grown organically since incorporation and in the year ended 31 March 2006 sales were approximately £2.1 million. As at 31 March 2006, the Company employed 22 staff at its 10,330 square foot facility in Alva, Central Scotland.

Omega operates in a niche market, in supplying tests for specific infectious diseases and other clinical conditions. The tests are based on Agglutination, Enzymeimmunoassay (EIA), Fluorescence and Rapid Test technologies. The infectious diseases include Syphilis, TB, Dengue Fever and Malaria.

All products are designed for use in Clinical Laboratories and Rapid Tests are designed for use at the point of care.

Omega currently exports over 95 per cent. of its products. Omega's export success was officially recognised with the Queen's Award for Export Achievement in 1993.

[tinker tailor] 31/8/2007 23:06

Really don't care about the Directors 30p holding as they are locked in and cannot sell until sometime in 2008.Shows even more confidence to me.

[snake_pleskin] 31/8/2007 23:04

They have now converted my oldholding into 13750 new shares but still not showing the ticker symbol to place an order(Selftrade). Directors as per normal got a gift of 100,000 shares at 30p..

[snake_pleskin] 31/8/2007 22:55

Tinker..I agree come monday this will fly, im glad im in with my converted shares and wish i had now got more when the price was at a penny. I will see how many i can get Monday morning. expect it will not be easy to get a sizeable quantity.